{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:16:06Z","timestamp":1791432966254,"version":"4.3.3"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X007413\/1"],"award-info":[{"award-number":["MR\/X007413\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Redox Biology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.redox.2026.104128","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:20:29Z","timestamp":1773458429000},"page":"104128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Sex-based differences in the NRF2 oxidative stress response: Implications for precision therapeutics"],"prefix":"10.1016","volume":"92","author":[{"given":"Giusy","family":"Russomanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Kwiatkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Copple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.redox.2026.104128_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102726","article-title":"The KEAP1-NRF2 pathway: targets for therapy and role in cancer","volume":"63","author":"Adinolfi","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2026.104128_bib2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1089\/ars.2023.0234","article-title":"The KEAP1-NRF2 system and neurodegenerative diseases","volume":"38","author":"Uruno","year":"2023","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.redox.2026.104128_bib3","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s11033-022-08126-1","article-title":"Dual role of Nrf2 in cancer: molecular mechanisms, cellular functions and therapeutic interventions","volume":"50","author":"Poornashree","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.redox.2026.104128_bib4","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.7150\/ijbs.98846","article-title":"Antioxidant genes in cancer and metabolic diseases: focusing on Nrf2, sestrin, and heme oxygenase 1","volume":"20","author":"Shrestha","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.redox.2026.104128_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076723","article-title":"Mitigation of cardiovascular disease and toxicity through NRF2 signalling","volume":"24","author":"Roberts","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.redox.2026.104128_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25225474","article-title":"An overview of Nrf2 signaling pathway and its role in inflammation","volume":"25","author":"Saha","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.redox.2026.104128_bib7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40120-024-00680-z","article-title":"Long-term safety and effectiveness of dimethyl fumarate in patients with multiple sclerosis treated in routine medical practice: final analysis of the ESTEEM study","volume":"14","author":"Pandey","year":"2025","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.redox.2026.104128_bib8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40265-023-01874-9","article-title":"Omaveloxolone: first approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.redox.2026.104128_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000486398","article-title":"Bardoxolone methyl improves kidney function in patients with chronic kidney disease stage 4 and type 2 diabetes: post-hoc analyses from bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes study","volume":"47","author":"Chin","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.redox.2026.104128_bib10","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1124\/dmd.114.059006","article-title":"Is nuclear factor erythroid 2-related factor 2 responsible for sex differences in susceptibility to acetaminophen-induced hepatotoxicity in mice?","volume":"42","author":"Rohrer","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.redox.2026.104128_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2023.111802","article-title":"Sex differences in antioxidant defence and the regulation of redox homeostasis in physiology and pathology","volume":"211","author":"Tiberi","year":"2023","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.redox.2026.104128_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41581-023-00787-w","article-title":"Mechanisms and consequences of sex differences in immune responses","volume":"20","author":"Dunn","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.redox.2026.104128_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/mol.109.056705","article-title":"Sex differences in the expression of hepatic drug metabolizing enzymes","volume":"76","author":"Waxman","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.redox.2026.104128_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.yexcr.2014.08.030","article-title":"Estrogen increases Nrf2 activity through activation of the PI3K pathway in MCF-7 breast cancer cells","volume":"328","author":"Wu","year":"2014","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.redox.2026.104128_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200004","article-title":"Activation of Nrf2 in the liver is associated with stress resistance mediated by suppression of the growth hormone-regulated STAT5b transcription factor","volume":"13","author":"Rooney","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.redox.2026.104128_bib16","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/ijc.35110","article-title":"Representation of women in clinical trials supporting FDA-Approval of contemporary cancer therapies","volume":"155","author":"Kalathoor","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.redox.2026.104128_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32597","article-title":"Sex as a biological variable in early-phase oncology clinical trials: enhancing the path to personalised medicine","volume":"10","author":"Sutherland","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.redox.2026.104128_bib18","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.cell.2022.04.012","article-title":"Precision medicine requires understanding how both sex and gender influence health","volume":"185","author":"Stachenfeld","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.redox.2026.104128_bib19","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1152\/physrev.00023.2017","article-title":"The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis","volume":"98","author":"Yamamoto","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.redox.2026.104128_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/mcb.00563-21","article-title":"The beta-TrCP-Mediated pathway cooperates with the Keap1-Mediated pathway in Nrf2 degradation in vivo","volume":"42","author":"Kuga","year":"2022","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.redox.2026.104128_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103885","article-title":"Bidirectional regulation of KEAP1 BTB domain-based sensor activity","volume":"87","author":"Suzuki","year":"2025","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2026.104128_bib22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/MCB.00868-15","article-title":"Characterizations of three major cysteine sensors of Keap1 in stress response","volume":"36","author":"Saito","year":"2016","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.redox.2026.104128_bib23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.celrep.2019.06.047","article-title":"Molecular mechanism of cellular oxidative stress sensing by Keap1","volume":"28","author":"Suzuki","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.redox.2026.104128_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21134777","article-title":"NRF2, a transcription factor for stress response and beyond","volume":"21","author":"He","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.redox.2026.104128_bib25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.tibs.2014.02.002","article-title":"The Nrf2 regulatory network provides an interface between redox and intermediary metabolism","volume":"39","author":"Hayes","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.redox.2026.104128_bib26","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1158\/1535-7163.MCT-10-0108","article-title":"Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype","volume":"9","author":"Singh","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.redox.2026.104128_bib27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.freeradbiomed.2022.07.013","article-title":"Nrf2 as a regulator of mitochondrial function: energy metabolism and beyond","volume":"189","author":"Esteras","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.redox.2026.104128_bib28","article-title":"The Nrf2 pathway in liver diseases","volume":"10","author":"Zhou","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.redox.2026.104128_bib29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jcmgh.2017.11.016","article-title":"Experimental nonalcoholic steatohepatitis and liver fibrosis are ameliorated by pharmacologic activation of Nrf2 (NF-E2 p45-Related factor 2)","volume":"5","author":"Sharma","year":"2018","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.redox.2026.104128_bib30","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.taap.2010.03.016","article-title":"Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet","volume":"245","author":"Zhang","year":"2010","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.redox.2026.104128_bib31","doi-asserted-by":"crossref","first-page":"G283","DOI":"10.1152\/ajpgi.00296.2009","article-title":"Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice","volume":"298","author":"Sugimoto","year":"2010","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.redox.2026.104128_bib32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/toxsci\/59.1.169","article-title":"High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes","volume":"59","author":"Enomoto","year":"2001","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.redox.2026.104128_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/305861","article-title":"Nrf2 protection against liver injury produced by various hepatotoxicants","author":"Liu","year":"2013","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.redox.2026.104128_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101393","article-title":"AMPK leads to phosphorylation of the transcription factor Nrf2, tuning transactivation of selected target genes","volume":"29","author":"Matzinger","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2026.104128_bib35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/toxsci\/kfn177","article-title":"Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid","volume":"106","author":"Maher","year":"2008","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.redox.2026.104128_bib36","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.molcel.2013.08.003","article-title":"Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy","volume":"51","author":"Ichimura","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.redox.2026.104128_bib37","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.devcel.2024.01.024","article-title":"SLAM-ITseq identifies that Nrf2 induces liver regeneration through the pentose phosphate pathway","volume":"59","author":"Tan","year":"2024","journal-title":"Dev. Cell"},{"key":"10.1016\/j.redox.2026.104128_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107423","article-title":"Nrf2 is involved in maintaining hepatocyte identity during liver regeneration","volume":"9","author":"Zou","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.redox.2026.104128_bib39","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/sj.emboj.7601950","article-title":"Impaired liver regeneration in Nrf2 knockout mice: role of ROS-mediated insulin\/IGF-1 resistance","volume":"27","author":"Beyer","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.redox.2026.104128_bib40","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/hep.31859","article-title":"Pharmacological activation of Nrf2 enhances functional liver regeneration","volume":"74","author":"Chan","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.redox.2026.104128_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10091463","article-title":"Nrf2 and heme Oxygenase-1 involvement in atherosclerosis related oxidative stress","volume":"10","author":"Alonso-Pineiro","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.redox.2026.104128_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101271","article-title":"Short-term pharmacological activation of Nrf2 ameliorates vascular dysfunction in aged rats and in pathological human vasculature. A potential target for therapeutic intervention","volume":"26","author":"Angulo","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2026.104128_bib43","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1161\/ATVBAHA.112.300345","article-title":"Myeloid deletion of nuclear factor erythroid 2-related factor 2 increases atherosclerosis and liver injury","volume":"32","author":"Collins","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.redox.2026.104128_bib44","doi-asserted-by":"crossref","first-page":"500","DOI":"10.21037\/cdt-20-126","article-title":"Up-regulation of PERK\/Nrf2\/HO-1 axis protects myocardial tissues of mice from damage triggered by ischemia-reperfusion through ameliorating endoplasmic reticulum stress","volume":"10","author":"Wang","year":"2020","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"10.1016\/j.redox.2026.104128_bib45","doi-asserted-by":"crossref","DOI":"10.1515\/med-2023-0711","article-title":"Nrf2 protects against myocardial ischemia-reperfusion injury in diabetic rats by inhibiting Drp1-mediated mitochondrial fission","volume":"18","author":"Wang","year":"2023","journal-title":"Open Med."},{"key":"10.1016\/j.redox.2026.104128_bib46","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1165\/rcmb.2009-0054OC","article-title":"Deletion of Keap1 in the lung attenuates acute cigarette smoke-induced oxidative stress and inflammation","volume":"42","author":"Blake","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.redox.2026.104128_bib47","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.resinv.2019.10.003","article-title":"Role of Nrf2 in the pathogenesis of respiratory diseases","volume":"58","author":"Mizumura","year":"2020","journal-title":"Respir. Investig."},{"key":"10.1016\/j.redox.2026.104128_bib48","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2174\/1570159X21666221129100308","article-title":"The role of Nrf2 in relieving cerebral ischemia-reperfusion injury","volume":"21","author":"Sun","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.redox.2026.104128_bib49","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1111\/febs.14379","article-title":"The role of Nrf2 signaling in counteracting neurodegenerative diseases","volume":"285","author":"Dinkova-Kostova","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.redox.2026.104128_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1437939","article-title":"Targeting the NRF2 pathway for disease modification in neurodegenerative diseases: mechanisms and therapeutic implications","volume":"15","author":"Mayer","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.redox.2026.104128_bib51","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1128\/MCB.00248-10","article-title":"A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62","volume":"30","author":"Lau","year":"2010","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.redox.2026.104128_bib52","doi-asserted-by":"crossref","first-page":"9109","DOI":"10.1093\/nar\/gkaa631","article-title":"NRF2 preserves genomic integrity by facilitating ATR activation and G2 cell cycle arrest","volume":"48","author":"Sun","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.redox.2026.104128_bib53","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s13402-023-00834-5","article-title":"Roles of NRF2 in DNA damage repair","volume":"46","author":"Li","year":"2023","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.redox.2026.104128_bib54","article-title":"Effects of the pharmacological modulation of NRF2 in cancer progression","volume":"61","author":"Gelerstein-Claro","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.redox.2026.104128_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1184079","article-title":"Nrf2 signaling pathway: current status and potential therapeutic targetable role in human cancers","volume":"13","author":"Lin","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.redox.2026.104128_bib56","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1158\/2159-8290.CD-21-0922","article-title":"NRF2: KEAPing tumors protected","volume":"12","author":"Pillai","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.redox.2026.104128_bib57","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/0008-5472.CAN-18-2723","article-title":"NRF2 activation in cancer: from DNA to protein","volume":"79","author":"Cloer","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.redox.2026.104128_bib58","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jtho.2019.07.003","article-title":"Mutations in the KEAP1-NFE2L2 pathway define a molecular subset of rapidly progressing lung adenocarcinoma","volume":"14","author":"Goeman","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.redox.2026.104128_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.578315","article-title":"Nrf2 mediates metabolic reprogramming in non-small cell lung cancer","volume":"10","author":"Zhao","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.redox.2026.104128_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.149536","article-title":"NRF2 mutation enhances the immune escape of hepatocellular carcinoma by reducing STING activation","volume":"698","author":"Li","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.redox.2026.104128_bib61","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41419-022-05126-8","article-title":"Genetic alterations of Keap1 confers chemotherapeutic resistance through functional activation of Nrf2 and notch pathway in head and neck squamous cell carcinoma","volume":"13","author":"Islam","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.redox.2026.104128_bib62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/ATVBAHA.110.210906","article-title":"NF-E2-related factor 2 promotes atherosclerosis by effects on plasma lipoproteins and cholesterol transport that overshadow antioxidant protection","volume":"31","author":"Barajas","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.redox.2026.104128_bib63","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.neuroscience.2015.07.057","article-title":"17beta-Estradiol up-regulates Nrf2 via PI3K\/AKT and estrogen receptor signaling pathways to suppress light-induced degeneration in rat retina","volume":"304","author":"Zhu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.redox.2026.104128_bib64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1474-9726.2005.00151.x","article-title":"17beta-oestradiol up-regulates longevity-related, antioxidant enzyme expression via the ERK1 and ERK2[MAPK]\/NFkappaB Cascade","volume":"4","author":"Borras","year":"2005","journal-title":"Aging Cell"},{"key":"10.1016\/j.redox.2026.104128_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/antiox8030069","article-title":"Mechanism of rapid nuclear Factor-E2-Related factor 2 (Nrf2) activation via membrane-associated estrogen receptors: roles of NADPH oxidase 1, neutral sphingomyelinase 2 and Epidermal Growth Factor Receptor (EGFR)","volume":"8","author":"Ishii","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.redox.2026.104128_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221650","article-title":"17-beta estradiol exerts anti-inflammatory effects through activation of Nrf2 in mouse embryonic fibroblasts","volume":"14","author":"Song","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.redox.2026.104128_bib67","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.WCB.0000125365.83980.00","article-title":"Progesterone enhances functional recovery after middle cerebral artery occlusion in male mice","volume":"24","author":"Gibson","year":"2004","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.redox.2026.104128_bib68","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/brain\/awr132","article-title":"Progesterone is neuroprotective following cerebral ischaemia in reproductively ageing female mice","volume":"134","author":"Gibson","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.redox.2026.104128_bib69","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.2147\/CMAR.S210004","article-title":"Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology","volume":"11","author":"Czogalla","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.redox.2026.104128_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.837603","article-title":"Testosterone contributes to vascular dysfunction in young mice fed a high fat diet by promoting nuclear factor E2-Related factor 2 downregulation and oxidative stress","volume":"13","author":"Costa","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.redox.2026.104128_bib71","article-title":"Amelioratory effects of testosterone propionate on age-related renal fibrosis via suppression of TGF-beta1\/Smad signaling and activation of Nrf2-ARE signaling","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.redox.2026.104128_bib72","article-title":"Diurnal variation of hepatic antioxidant gene expression in mice","volume":"7","author":"Xu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.redox.2026.104128_bib73","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1124\/dmd.120.000181","article-title":"Sex-, Age-, and Race\/ethnicity-dependent variations in drug-processing and NRF2-Regulated genes in human livers","volume":"49","author":"Liu","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.redox.2026.104128_bib74","article-title":"NRF2 deficiency increases obesity susceptibility in a mouse menopausal model","volume":"15","author":"Wu","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.redox.2026.104128_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/cells13151247","article-title":"Sex differences affect the NRF2 signaling pathway in the early phase of liver steatosis: a high-fat-diet-fed rat model supplemented with liquid fructose","volume":"13","author":"Di Veroli","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.redox.2026.104128_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111610","article-title":"Sex differences in resilience to ferroptosis underlie sexual dimorphism in kidney injury and repair","volume":"41","author":"Ide","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.redox.2026.104128_bib77","doi-asserted-by":"crossref","first-page":"F149","DOI":"10.1152\/ajprenal.00099.2020","article-title":"Sex differences in renal ischemia-reperfusion injury","volume":"319","author":"Hosszu","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.redox.2026.104128_bib78","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00109-022-02227-x","article-title":"Epigenetic mechanisms regulate sex-specific bias in disease manifestations","volume":"100","author":"Chlamydas","year":"2022","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.redox.2026.104128_bib79","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.freeradbiomed.2015.06.013","article-title":"Epigenetic regulation of Keap1-Nrf2 signaling","volume":"88","author":"Guo","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.redox.2026.104128_bib80","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jid.2017.09.054","article-title":"Sexual dimorphism in response to an NRF2 inducer in a model for pachyonychia congenita","volume":"138","author":"Kerns","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.redox.2026.104128_bib81","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1007\/s11095-011-0500-z","article-title":"Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice","volume":"28","author":"Clarke","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.redox.2026.104128_bib82","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.038505","article-title":"Omaveloxolone, but not dimethyl fumarate, improves cardiac function in friedreich's ataxia mice with severe cardiomyopathy","volume":"14","author":"Salinas","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.redox.2026.104128_bib83","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13293-024-00589-0","article-title":"Nrf2 activation rescues stress-induced depression-like behaviour and inflammatory responses in male but not female rats","volume":"15","author":"McCallum","year":"2024","journal-title":"Biol. Sex Differ."},{"key":"10.1016\/j.redox.2026.104128_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101488","article-title":"Sex differences in the response to oxidative and proteolytic stress","volume":"31","author":"Tower","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2026.104128_bib85","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/jwh.2005.14.19","article-title":"Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics","volume":"14","author":"Anderson","year":"2005","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.redox.2026.104128_bib86","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.redox.2026.104128_bib87","volume":"5\u201315","author":"Kinsley","year":"2016"},{"key":"10.1016\/j.redox.2026.104128_bib88","article-title":"Biological sex differences in pharmacokinetics and adverse drug reactions","author":"Aljohmani","year":"2025","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.redox.2026.104128_bib89","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2174\/1389200220666191021094906","article-title":"Sexual dimorphism in drug metabolism and pharmacokinetics","volume":"20","author":"Valodara","year":"2019","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.redox.2026.104128_bib90","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/BF01297133","article-title":"Fasting gastric pH and its relationship to true hypochlorhydria in humans","volume":"36","author":"Feldman","year":"1991","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.redox.2026.104128_bib91","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5534\/wjmh.190009","article-title":"Sex differences in gut microbiota","volume":"38","author":"Kim","year":"2020","journal-title":"World J. Mens Health"},{"key":"10.1016\/j.redox.2026.104128_bib92","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijpharm.2011.04.069","article-title":"Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery","volume":"415","author":"Freire","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.redox.2026.104128_bib93","doi-asserted-by":"crossref","first-page":"314","DOI":"10.5056\/jnm20208","article-title":"Roles of sex hormones and gender in the gut microbiota","volume":"27","author":"Yoon","year":"2021","journal-title":"J. Neurogastroenterol. Motil."},{"key":"10.1016\/j.redox.2026.104128_bib94","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11906-023-01244-6","article-title":"Sexual dimorphic interplays between gut microbiota and antihypertensive drugs","volume":"25","author":"Bardhan","year":"2023","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.redox.2026.104128_bib95","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1021\/acs.molpharmaceut.0c00574","article-title":"Quantification of P-Glycoprotein in the gastrointestinal tract of humans and rodents: methodology, gut region, sex, and species matter","volume":"18","author":"Mai","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.redox.2026.104128_bib96","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/ndt\/gfl227","article-title":"Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors","volume":"21","author":"Berg","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.redox.2026.104128_bib97","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/clpt.1993.104","article-title":"Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine","volume":"54","author":"Gaudry","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.redox.2026.104128_bib98","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00003088-200342020-00001","article-title":"The influence of sex on pharmacokinetics","volume":"42","author":"Schwartz","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.redox.2026.104128_bib99","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1177\/0091270008323754","article-title":"Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs","volume":"48","author":"Greenblatt","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.redox.2026.104128_bib100","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0006-2952(92)90010-G","article-title":"Effect of age and gender on the activity of human hepatic CYP3A","volume":"44","author":"Hunt","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.redox.2026.104128_bib101","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1365-2710.1999.00246.x","article-title":"Gender-related differences in pharmacokinetics and their clinical significance","volume":"24","author":"Tanaka","year":"1999","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.redox.2026.104128_bib102","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1517\/17425255.4.4.413","article-title":"Sex-specific differences in CYP450 isoforms in humans","volume":"4","author":"Scandlyn","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.redox.2026.104128_bib103","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/bdd.680","article-title":"Nrf2 plays an important role in coordinated regulation of phase II drug metabolism enzymes and phase III drug transporters","volume":"30","author":"Shen","year":"2009","journal-title":"Biopharm Drug Dispos."},{"key":"10.1016\/j.redox.2026.104128_bib104","article-title":"Effect of graded Nrf2 activation on phase-I and -II drug metabolizing enzymes and transporters in mouse liver","volume":"7","author":"Wu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.redox.2026.104128_bib105","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/0091270007299930","article-title":"Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs","volume":"47","author":"Urquhart","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.redox.2026.104128_bib106","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.addr.2010.08.006","article-title":"Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR","volume":"62","author":"Tolson","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.redox.2026.104128_bib107","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3109\/07420528.2013.805762","article-title":"Sex differences in the circadian variation of cytochrome p450 genes and corresponding nuclear receptors in mouse liver","volume":"30","author":"Lu","year":"2013","journal-title":"Chronobiol. Int."},{"key":"10.1016\/j.redox.2026.104128_bib108","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40168-021-01050-9","article-title":"The pregnane X receptor drives sexually dimorphic hepatic changes in lipid and xenobiotic metabolism in response to gut microbiota in mice","volume":"9","author":"Barretto","year":"2021","journal-title":"Microbiome"},{"key":"10.1016\/j.redox.2026.104128_bib109","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/sj.ki.5001880","article-title":"Gender differences in renal nuclear receptors and aryl hydrocarbon receptor in 5\/6 nephrectomized rats","volume":"70","author":"Lu","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.redox.2026.104128_bib110","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1124\/dmd.112.045112","article-title":"Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARalpha-, and Nrf2-null mice","volume":"40","author":"Aleksunes","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.redox.2026.104128_bib111","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00128071-200102060-00001","article-title":"Do women have more adverse drug reactions?","volume":"2","author":"Rademaker","year":"2001","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.redox.2026.104128_bib112","first-page":"1254","article-title":"Sex-based differences in drug activity","volume":"80","author":"Whitley","year":"2009","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.redox.2026.104128_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.10.001","article-title":"Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century","volume":"17","author":"Watson","year":"2019","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.redox.2026.104128_bib114","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.redox.2026.104128_bib115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1472-6904-7-9","article-title":"Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005","volume":"7","author":"Patel","year":"2007","journal-title":"BMC Clin. Pharmacol."},{"key":"10.1016\/j.redox.2026.104128_bib116","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2125.2010.03811.x","article-title":"Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands","volume":"71","author":"Rodenburg","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.redox.2026.104128_bib117","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tips.2022.12.003","article-title":"Advances and challenges in therapeutic targeting of NRF2","volume":"44","author":"Dinkova-Kostova","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.redox.2026.104128_bib118","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.redox.2026.104128_bib119","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1124\/molpharm.123.000671","article-title":"A point mutation at C151 of Keap1 of mice abrogates NRF2 signaling, cytoprotection in vitro, and hepatoprotection in vivo by bardoxolone methyl (CDDO-Me)","volume":"104","author":"Gatbonton-Schwager","year":"2023","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.redox.2026.104128_bib120","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1158\/1078-0432.CCR-11-2703","article-title":"A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas","volume":"18","author":"Hong","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.redox.2026.104128_bib121","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.redox.2026.104128_bib122","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.redox.2026.104128_bib123","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.redox.2026.104128_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tips.2017.11.002","article-title":"The pharmacokinetics of fumaric acid esters reveal their in vivo effects","volume":"39","author":"Mrowietz","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.redox.2026.104128_bib125","series-title":"Auspar: Dimethyl Fumarate","year":"2013"},{"key":"10.1016\/j.redox.2026.104128_bib126","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.autrev.2018.07.001","article-title":"Dimethyl fumarate treatment in multiple sclerosis: recent advances in clinical and immunological studies","volume":"17","author":"Montes Diaz","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.redox.2026.104128_bib127","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s40265-019-01229-3","article-title":"Dimethyl fumarate: a review in relapsing-remitting MS","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.redox.2026.104128_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107710","article-title":"Dimethyl fumarate induced lymphopenia in multiple sclerosis: a review of the literature","volume":"219","author":"Dello Russo","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.redox.2026.104128_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104081","article-title":"Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis","volume":"67","author":"Ravn","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.redox.2026.104128_bib130","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jnnp-2022-328994","article-title":"Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis","volume":"93","author":"Magyari","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.redox.2026.104128_bib131","article-title":"Impact of sex on multiple sclerosis therapy","volume":"22","author":"Coyle","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.redox.2026.104128_bib132","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.msard.2017.01.001","article-title":"Sex differences in outcomes of disease-modifying treatments for multiple sclerosis: a systematic review","volume":"12","author":"Li","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.redox.2026.104128_bib133","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.yfrne.2018.07.001","article-title":"A case for gender-based approach to multiple sclerosis therapeutics","volume":"50","author":"Houtchens","year":"2018","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.redox.2026.104128_bib134","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1073\/pnas.0500815102","article-title":"Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress","volume":"102","author":"Dinkova-Kostova","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.redox.2026.104128_bib135","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molmed.2023.12.002","article-title":"Omaveloxolone: a groundbreaking milestone as the first FDA-Approved drug for friedreich ataxia","volume":"30","author":"Pilotto","year":"2024","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.redox.2026.104128_bib136","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fncel.2018.00188","article-title":"Novel Nrf2-Inducer prevents mitochondrial defects and oxidative stress in friedreich's ataxia models","volume":"12","author":"Abeti","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.redox.2026.104128_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.952950","article-title":"Omaveloxolone inhibits IL-1beta-induced chondrocyte apoptosis through the Nrf2\/ARE and NF-kappaB signalling pathways in vitro and attenuates osteoarthritis in vivo","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.redox.2026.104128_bib138","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122942","article-title":"RTA 408, A novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity","volume":"10","author":"Probst","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.redox.2026.104128_bib139","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.2147\/OTT.S136992","article-title":"Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors","volume":"10","author":"Creelan","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.redox.2026.104128_bib140","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/jcph.6189","article-title":"Clinical assessment of the drug-drug interaction potential of omaveloxolone in healthy adult participants","volume":"65","author":"Zahir","year":"2025","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.redox.2026.104128_bib141","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of omaveloxolone in friedreich ataxia (MOXIe Study)","volume":"89","author":"Lynch","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.redox.2026.104128_bib142","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of omaveloxolone in friedreich's ataxia: delayed-start analysis of the MOXIe extension","volume":"38","author":"Lynch","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.redox.2026.104128_bib143","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/acn3.51897","article-title":"Propensity matched comparison of omaveloxolone treatment to friedreich ataxia natural history data","volume":"11","author":"Lynch","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.redox.2026.104128_bib144","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s40120-025-00749-3","article-title":"Safety monitoring of omaveloxolone in friedreich ataxia: results from one year of clinical treatment","volume":"14","author":"Gunther","year":"2025","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.redox.2026.104128_bib145","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s40120-025-00752-8","article-title":"Managing aminotransferase elevations in patients with friedreich ataxia treated with omaveloxolone: a review and expert opinion on use considerations","volume":"14","author":"Perlman","year":"2025","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.redox.2026.104128_bib146","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00415-025-13487-1","article-title":"Early experience on omaveloxolone in adult patients with friedreich's ataxia: a real-world observational study","volume":"272","author":"Lima","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.redox.2026.104128_bib147","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030916","article-title":"The NRF2 signaling network defines clinical biomarkers and therapeutic opportunity in friedreich's ataxia","volume":"21","author":"La Rosa","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.redox.2026.104128_bib148","doi-asserted-by":"crossref","DOI":"10.3390\/cells14181406","article-title":"Oxidative stress and antioxidant therapies in friedreich's ataxia","volume":"14","author":"Jimenez-Jimenez","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.redox.2026.104128_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101435","article-title":"Estrogenic control of mitochondrial function","volume":"31","author":"Klinge","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2026.104128_bib150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pneurobio.2019.03.001","article-title":"Effects of estrogens and androgens on mitochondria under normal and pathological conditions","volume":"176","author":"Mohajeri","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.redox.2026.104128_bib151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7742(08)00001-9","article-title":"Gender differences in pharmacological response","volume":"83","author":"Anderson","year":"2008","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.redox.2026.104128_bib152","doi-asserted-by":"crossref","first-page":"H640","DOI":"10.1152\/ajpheart.00864.2013","article-title":"Sex differences in the mechanisms underlying long QT syndrome","volume":"307","author":"Salama","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.redox.2026.104128_bib153","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/bcp.12201","article-title":"Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol","volume":"77","author":"Darpo","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.redox.2026.104128_bib154","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/ehjcvp\/pvw042","article-title":"Gender differences in the effects of cardiovascular drugs","volume":"3","author":"Tamargo","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother"},{"key":"10.1016\/j.redox.2026.104128_bib155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrcardio.2015.110","article-title":"Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms","volume":"13","author":"Frommeyer","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.redox.2026.104128_bib156","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s13105-023-00957-1","article-title":"Regulation of ABC transporters by sex steroids May explain differences in drug resistance between sexes","volume":"79","author":"Mineiro","year":"2023","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/j.redox.2026.104128_bib157","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2022.844916","article-title":"Sex differences in blood-brain barrier transport of psychotropic drugs","volume":"16","author":"Dalla","year":"2022","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.redox.2026.104128_bib158","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-12342-7","article-title":"Analysis of sex-differential gene expression on the target of approved drug","volume":"15","author":"Suh","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.redox.2026.104128_bib159","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1096\/fj.201600781r","article-title":"Considering sex as a biological variable in preclinical research","volume":"31","author":"Miller","year":"2017","journal-title":"FASEB J."},{"key":"10.1016\/j.redox.2026.104128_bib160","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1210\/clinem\/dgab434","article-title":"The integration of sex and gender considerations into biomedical research: lessons from international funding agencies","volume":"106","author":"White","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.redox.2026.104128_bib161","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s44294-024-00027-x","article-title":"Integrating sex and gender into biomedical research requires policy and culture change","volume":"2","author":"Witt","year":"2024","journal-title":"NPJ Womens Health"}],"container-title":["Redox Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231726001266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231726001266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T19:32:41Z","timestamp":1776713561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213231726001266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":161,"alternative-id":["S2213231726001266"],"URL":"https:\/\/doi.org\/10.1016\/j.redox.2026.104128","relation":{},"ISSN":["2213-2317"],"issn-type":[{"value":"2213-2317","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex-based differences in the NRF2 oxidative stress response: Implications for precision therapeutics","name":"articletitle","label":"Article Title"},{"value":"Redox Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.redox.2026.104128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104128"}}